Skip to main content

03-04-2021 | Semaglutide | Commentary | Article

STEP 2: A higher semaglutide dose in people with type 2 diabetes

Ildiko Lingvay discusses the STEP 2 findings, and why a higher semaglutide dose may be optimal for most people with type 2 diabetes (8:06).

Keep up with the latest results from the STEP trials

About the speaker

Ildiko Lingvay

Ildiko Lingvay is Professor in the Division of Endocrinology and the Department of Population and Data Sciences at the University of Texas (UT) Southwestern Medical Center in Dallas, TX, USA.

Full biography

Semaglutide for weight loss: The STEP and SELECT trials

Get the latest results and insights from the researchers.

Image Credits